Remove Competition Remove Healthcare Remove Patients Remove Pharmaceutical manufacturing
article thumbnail

Should we be worried about pharma’s supply chain?

World of DTC Marketing

QUICK READ: Pharma supply chain issues are a concern for us all but especially patients. Patients should be scared. We need a 21st-century approach that puts patient safety first. The adulterated product was found to have caused nine patient deaths and 574 serious adverse events (SAEs). In other words, money over safety.

article thumbnail

US legislative update: takeaways for European pharma

European Pharmaceutical Review

Pharmaceutical manufacturers have submitted Citizen Petitions raising safety or efficacy concerns about proposed competing generic and biosimilar products, and such submissions often delay FDA approval of the proposed products while the FDA resolves the pending petitions. Conclusion.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Economics and risks of FDA’s Quality management maturity rating programme

European Pharmaceutical Review

The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) through the Office of Pharmaceutical Quality in 2021 embarked on an initiative to develop a framework for establishing a pharmaceutical manufacturing site quality rating system, the Quality management maturity (QMM) programme.

article thumbnail

Top 5 Emerging Trends in Pharma Industry

Medico Reach

The global pharmaceutical manufacturing market stood at USD 405.52 The paradigm shift towards integrated, intelligent, and data-rich technologies is propelling the growth of medicines manufacturing. Here are some more applications of AI in healthcare and pharma Medicines discovery and design can improve drastically.

Pharma 52
article thumbnail

What factors are driving life sciences FDI in 2022?

Pharmaceutical Technology

Linked to talent, the presence of good universities is another great sign for life sciences, especially institutions with a focus on healthcare. Real estate options, schools, recreational and cultural amenities, healthcare systems, cost of living, transportation, crime and climate are all key considerations.

article thumbnail

Biosimilars Market Set for Biggest Year Yet in 2023

PM360

Although AbbVie’s patent for Humira officially expired in 2016, the legal and regulatory delays paused competition for Humira until 2023. pharmaceutical industry. Switching patients from brand to biosimilar, as well as between biosimilars, was also highlighted in the survey.

article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

The healthcare industry is successful in innovating new treatment paradigms ranging from small molecular to biological therapeutics to personalised medicines. The healthcare industry is successful in innovating new treatment paradigms ranging from small molecular to biological therapeutics to personalised medicines.